Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 20/20 | 0.61 |
| ▸ | EED | O75530 | 2/20 | 0.59 |
| ▸ | RBBP4 | Q09028 | 2/20 | 0.59 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.59 |
| ▸ | RBBP7 | Q16576 | 2/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10257356 | 0.86 | EZH2 (0.74) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10259704 | 0.86 | EZH2 (0.67) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL14739978 | 0.84 | EZH2 (0.69) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10254776 | 0.84 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL16248356 | 0.84 | EZH2 (0.66) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL14740246 | 0.83 | EZH2 (0.69) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10256644 | 0.83 | EZH2 (0.71) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10255294 | 0.82 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL1695310 | 0.82 | EZH2 (0.73) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL10255375 | 0.82 | EZH2 (0.70) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | claimed |
| EP-2755962-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2014-07-23 | — | — | EP | claimed |
| US-8637509-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2014-01-28 | — | — | US | claimed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | claimed |
| EP-2566479-A1 | AZAINDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | claimed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | claimed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | claimed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2566479-B1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-12-24 | — | — | EP | disclosed |
| US-20140343056-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2013067302-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039988-A1 | AZAINDAZOLES | GLAX0SMITHKLINE LLC (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| US-20130059849-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC | 2013-03-07 | — | — | US | disclosed |
| WO-2012005805-A1 | AZAINDAZOLES | GLAXOSMITHKLINE LLC (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343056-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | EZH2 58/4885EED 454/4885RBBP4 874/4885 |
| US-20130059849-A1 | AZAINDAZOLES | AZI2, MKI67, DNMT1 | EZH2 58/4885EED 454/4885RBBP4 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.